Neuroregeneration Therapy

A Global Strategic Business Report

MCP34123

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

7512

EXECUTIVE POOL

5850

PRICE

823

EXPERT INPUTS

42

COMPANIES

408

DATA TABLES

480

PAGES

2

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (55)

3

CXO

5

VICE PRESIDENT

10

DIRECTOR

25

MANAGER

12

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Neuroregeneration Therapy Market to Reach US$47.2 Billion by 2030

The global market for Neuroregeneration Therapy estimated at US$37.8 Billion in the year 2024, is expected to reach US$47.2 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. N-methyl-D-aspartate Receptor Antagonists, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.9 Billion by the end of the analysis period. Growth in the Cholinesterase Inhibitors segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.3 Billion While China is Forecast to Grow at 7.0% CAGR

The Neuroregeneration Therapy market in the U.S. is estimated at US$10.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.5 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Neuroregeneration Therapy Market – Key Trends & Drivers Summarized

Why Is Neuroregeneration Therapy Gaining Global Momentum in the Treatment of CNS and PNS Injuries?

Neuroregeneration therapy is emerging as a frontier area in neuroscience and regenerative medicine, offering hope for patients suffering from central and peripheral nervous system damage. Traditionally considered irreversible, neural injuries caused by trauma, stroke, neurodegenerative diseases, or demyelination are now being targeted with interventions that promote axonal regrowth, synaptic reformation, remyelination, and functional recovery. This paradigm shift from symptomatic management to actual nerve tissue repair is revolutionizing neurological rehabilitation and positioning neuroregeneration as a cornerstone of future neurotherapeutics.

The demand for neuroregeneration therapy is driven by the increasing global incidence of spinal cord injuries, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and traumatic brain injuries. With an aging population and rising road traffic accidents and sports-related traumas, the number of individuals suffering from debilitating neurological impairments continues to rise. Traditional therapies offer limited recovery potential and focus largely on slowing disease progression. In contrast, neuroregeneration therapies aim to restore lost function, giving rise to a new generation of curative, rather than palliative, treatment strategies.

How Are Emerging Modalities Like Stem Cells, Growth Factors, and Gene Therapies Transforming Neuroregeneration?

The technological core of neuroregeneration therapy revolves around cutting-edge biologics and engineered cell systems. Stem cell therapy—particularly mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and neural progenitor cells—is one of the most advanced approaches under clinical development. These cells secrete neurotrophic factors, modulate inflammation, and differentiate into neuron-like cells that aid in repairing damaged neural tissue. Clinical trials are exploring their use in spinal cord injuries, stroke recovery, ALS, and multiple sclerosis with promising early results.

Growth factor therapies—including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF)—are being delivered through viral vectors, biomaterials, or direct infusion to promote neuronal survival and plasticity. Gene therapies targeting neuroinflammation, myelin repair, or synaptic dysfunction are showing potential, especially in hereditary neurodegenerative diseases. Advances in biomaterial scaffolds, hydrogel matrices, and neural interfaces are also enabling localized, sustained delivery of these regenerative agents. These innovations are redefining therapeutic expectations, emphasizing neural restoration and circuit reintegration over mere symptom suppression.

Which Clinical Applications and Patient Populations Are Shaping the Neuroregeneration Market Landscape?

Neuroregeneration therapy is being investigated across a wide range of clinical applications, including spinal cord injuries, traumatic brain injuries (TBIs), peripheral nerve injuries, ischemic stroke, multiple sclerosis, and neurodegenerative diseases such as ALS and Parkinson’s. Patients with chronic neural damage—especially those with partial residual function or early-stage degeneration—are currently the best candidates for regenerative intervention. The pediatric neurology segment, particularly in cerebral palsy and congenital neural tube defects, is also a target for future therapeutic innovation.

Regions with high incidence of neurotrauma, stroke, and aging-related neurodegeneration—such as North America, Europe, and Asia-Pacific—are driving clinical trial activity and market demand. The U.S. leads in terms of regulatory progress and stem cell clinical infrastructure, while Japan and South Korea are advancing regenerative trials under favorable regulatory regimes. Emerging markets in Latin America and the Middle East are investing in rehabilitation infrastructure and international trial participation, enabling wider access to experimental regenerative therapies. Increasing patient advocacy and awareness of clinical trial participation are further broadening the market’s reach.

What Is Driving Long-Term Growth and Innovation in the Neuroregeneration Therapy Market?

The growth in the neuroregeneration therapy market is driven by the convergence of stem cell biology, biomaterials science, molecular neurobiology, and precision gene editing. The recognition of the nervous system’s plasticity and the ability to stimulate endogenous repair mechanisms is shifting the clinical approach to neural injuries. Regulatory frameworks for advanced therapy medicinal products (ATMPs) are being refined to accelerate the development and commercialization of regenerative neurotherapies. Public and private investment in neurorestorative research is expanding, with cross-disciplinary collaboration fueling innovation.

Clinical validation, scalable manufacturing, ethical sourcing, and long-term safety monitoring remain critical challenges. However, as data from early-phase trials mature, and as delivery technologies become more refined, a growing number of neuroregeneration products are expected to reach market approval. The increasing integration of digital neurorehabilitation tools, wearable neurostimulation devices, and remote patient monitoring systems will further enhance treatment adherence and outcome tracking. As neuroregeneration becomes a key pillar of neurotherapeutics, it will play a transformative role in improving functional recovery and quality of life for millions worldwide.

SCOPE OF STUDY

The report analyzes the Neuroregeneration Therapy market by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Other Drug Types); Indication Type (Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication, Other Indications); Administration Route (Oral Route, Parenteral Route, Transdermal Route); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Online Pharmacies End-Use).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..

SELECT PLAYERS

Abbott Laboratories; Acadia Pharmaceuticals Inc.; Alector, Inc.; Anavex Life Sciences Corp.; Annovis Bio, Inc.; AstraZeneca plc; Biogen Inc.; Boston Scientific Corporation; Ceregene, Inc.; Coave Therapeutics; Denali Therapeutics Inc.; Integra LifeSciences Holdings Corp.; Medtronic plc; Merck & Co., Inc.; NeuExcell Therapeutics; Neurona Therapeutics, Inc.; Novartis AG; Pfizer Inc.; Polyganics B.V.; Teva Pharmaceutical Industries Ltd.;

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

World Market Trajectories

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Neuroregeneration Therapy – Global Key Competitors Percentage Market Share in 2025 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 42 Players Worldwide in 2025 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Growing Understanding of CNS Plasticity Mechanisms Spurs Innovation in Neuroregeneration Therapies

Increased Incidence of Spinal Cord Injury and Stroke Expands Addressable Market for Regenerative Interventions

Emergence of Stem Cell and iPSC-Based Approaches Propels Growth in Cell Therapy Pipelines

Rising Investment in Neurotrophic Factor Research Enhances Drug Discovery Potential

Availability of Gene Therapy Vectors Strengthens Business Case for Precision Regeneration

Advances in Bioactive Scaffolds and Hydrogels Accelerate Adoption of Tissue Engineering Solutions

Integration of Electrical Stimulation Techniques Drives Synaptic Recovery and Functional Restoration

Global Increase in Neurotrauma-Linked Disabilities Sustains Demand for Regenerative Solutions

Adoption of 3D Bioprinting for Neural Tissue Constructs Throws the Spotlight on Personalized Regeneration

Expansion of Academic-Industry Collaborations Spurs Translational Neuroregeneration Research

Improved Preclinical Models Enhance Efficacy Validation in Early-Stage Drug Development

Rising Regulatory Support for Regenerative Medicines Drives Clinical Trial Approvals

Integration of AI in Cell Therapy Manufacturing Optimizes Scalability and Quality Control

Growing Availability of Companion Diagnostics Enhances Therapy Precision and Targeting

Limited Efficacy of Current Neurorestorative Therapies Strengthens Demand for Breakthrough Solutions

Public-Private Investments in Brain Injury Recovery Programs Accelerate Product Commercialization

Development of Nanocarrier-Based Delivery Systems Supports Efficient Neurotrophic Transport

Growing Pipeline for ALS, MS, and Parkinson's Disease Drives Diversified Applications

Complexities in Long-Term Efficacy and Safety Tracking Pose Clinical Trial Design Challenges

Increased Reimbursement Coverage for Cell-Based Therapies Expands Patient Accessibility

Technological Advancements in Live Imaging and CNS Mapping Facilitate Outcome Monitoring

4. GLOBAL MARKET PERSPECTIVE

World Neuroregeneration Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Neuroregeneration Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for N-methyl-D-aspartate Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for N-methyl-D-aspartate Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for N-methyl-D-aspartate Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Immunomodulatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Transdermal Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Transdermal Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Transdermal Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Hospital Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Retail Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Online Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Parkinson’s Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Parkinson’s Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Parkinson’s Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Alzheimer’s Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Alzheimer’s Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Alzheimer’s Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Multiple Sclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

JAPAN

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

CHINA

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

EUROPE

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Review for Neuroregeneration Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

FRANCE

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

GERMANY

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

UNITED KINGDOM

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

SPAIN

Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

RUSSIA

Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Neuroregeneration Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

AUSTRALIA

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)

Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

INDIA

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)

India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

India Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

SOUTH KOREA

South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

REST OF ASIA-PACIFIC

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

LATIN AMERICA

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)

Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Latin America Historic Review for Neuroregeneration Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

ARGENTINA

Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

BRAZIL

Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

MEXICO

Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

REST OF LATIN AMERICA

Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

MIDDLE EAST

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)

Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR

Middle East Historic Review for Neuroregeneration Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

IRAN

Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

ISRAEL

Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

SAUDI ARABIA

Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

UNITED ARAB EMIRATES

UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

REST OF MIDDLE EAST

Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

AFRICA

Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)

Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson’s Disease Indication, Alzheimer’s Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
Merz Pharma GmbH & Co. KGaA	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll